Type 2 biologics reduced mucus plugs in asthma trials, and quantitative imaging may help detect this treatable phenotype, according to a GOLD 2026 session.
|Videos|September 8, 2021
Lung Cancer Screening & Treatment: What Comes Next?
Author(s)HCP Live
The pulmonology and oncology expert panel returns for another discussion on lung cancer treatment challenges presented by the pandemic—and how the field can recover.
Advertisement
Advertisement
Related to this article
CT-detected mucus plugs affect up to 67% of patients with COPD and are linked to worse lung function, exacerbations, and mortality, even without symptoms.
Robert Mentz, MD, discusses mentorship, trial recruitment, journal growth, and surgical partnerships in heart failure care.
At GOLD 2026, Alvar Agustí, MD, PhD, speaks on COPD underdiagnosis and misdiagnosis, barriers to spirometry in primary care, and managing pre-COPD.
In a 50-patient rhinovirus challenge study, a single nasal ETH47 dose cut peak viral load 40-fold, though the primary endpoint was not significant.
October 2026 pulmonology highlights include FDA accelerated approval of Voceryq for recurrent respiratory papillomatosis and CHEST 2026 data.
HCPLive previews GOLD 2026 in Philadelphia, November 5-6, with sessions on the 2027 GOLD Report, mucus plugging, and exacerbations, plus expert interviews.
In 20 patients with PAH, lower baseline RVEF was linked to greater RV functional recovery and PVR reduction after 24 weeks of sotatercept, per a CHEST 2026 abstract.
Advertisement
Advertisement
Trending on HCPLive
1
Real-World Resmetirom Data Show Liver Stiffness Gains in MASH
2
IDEAL: Seladelpar Achieves ALP Normalization in Second-Line PBC
3
ELSPIRE: Elafibranor Achieves ALP Normalization in 85% With PBC
4
Conference Preview: 2026 GOLD International COPD Conference
5